Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment

被引：0

作者：

Wang, Michael L. ^{[1
]}

Shah, Nirav N. ^{[2
]}

Jurczak, Wojciech ^{[3
,6
]}

Zinzani, Pier Luigi ^{[4
,5
]}

Eyre, Toby A.

Cheah, Chan Y. ^{[7
,8
,9
]}

Ujjani, Chaitra S. ^{[10
]}

Izutsu, Koji ^{[11
]}

Ma, Shuo ^{[12
]}

Flinn, Ian ^{[13
]}

Alencar, Alvaro J. ^{[14
]}

Lewis, David ^{[15
]}

Patel, Krish ^{[16
]}

Maddocks, Kami ^{[17
]}

Wang, Yucai ^{[18
]}

Munir, Talha ^{[19
]}

Zelenetz, Andrew D. ^{[20
]}

Balbas, Minna ^{[21
]}

Tsai, Donald E. ^{[21
]}

Wang, Chunxiao ^{[22
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[3] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[4] IRCCS Azienda Osped Univ Bologna Ist Ematol, Seragnoli, Italy

[5] Univ Bologna, Dipartimento Med Specialist Diag & Sperimentale, Bologna, Italy

[6] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[7] Linear Clin Res, Perth, WA, Australia

[8] Sir Charles Gairdner Hosp, Perth, WA, Australia

[9] Univ Western Australia, Med Sch, Perth, WA, Australia

[10] Univ Washington, Fred Hutchinson Canc Res Ctr, Washington, DC USA

[11] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[12] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[13] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA

[14] Sylvester Comprehens Canc Ctr, Miami, FL USA

[15] Plymouth Hosp NHS Trust Derriford Hosp, Plymouth, Devon, England

[16] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA

[17] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[18] Mayo Clin, Div Hematol, Rochester, MN USA

[19] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[20] Memorial Sloan Kettering Canc Ctr, New York, NY USA

[21] Loxo Lilly, Indianapolis, IN USA

[22] Eli Lilly & Co, Indianapolis, IN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

MCL; BTK-inhibitor; pirtobrutinib; TP53; mutation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MCL-155

引用

页码：S459 / S459

页数：1

共 50 条

[21] Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results fro the Phase 1/2 BRUIN Study
Mato, Anthony R.
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Munir, Tahla
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Yoon
Cohen, Jonathon B.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David John
Gerson, James N.
Alencar, Alvaro J.
Ujjani, Chaitra S.
Flinn, Ian W.
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
BLOOD, 2021, 138
[22] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
Wierda, William G.
Lewis, David John
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Lamanna, Nicole
Rhodes, Joanna M.
Hoffmann, Marc
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
BLOOD, 2022, 140
[23] Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
Rhodes, Joanna
Lewis, David
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Woyach, Jennifer
Lamanna, Nicole
Hoffmann, Marc S.
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
Wierda, William G.
CANCER RESEARCH, 2023, 83 (08)
[24] Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18Month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Wierda, William G.
Shah, Nirav N.
Cheah, Chan Yoon
Lewis, David
Hoffmann, Marc S.
Coombs, Catherine C.
Lamanna, Nicole
Ma, Shuo
Jagadeesh, Deepa
Munir, Talha
Wang, Yucai
Eyre, Toby A.
Rhodes, Joanna M.
McKinney, Matthew
Lech-Maranda, Ewa
Tam, Constantine S.
Jurczak, Wojciech
Izutsu, Koji
Alencar, Alvaro J.
Patel, Manish
Seymour, John F.
Woyach, Jennifer A.
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo
Ho, Caleb
Marella, Narasimha
Wang, Chunxiao
Ruppert, Amy S.
Nair, Binoj Chandrasekharan
Liu, Hui
Tsai, Donald E.
Ghia, Paolo
BLOOD, 2023, 142
[25] BRUIN MCL-321, a Phase 3 OpenLabel, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress)
Ito, Rodrigo
Eyre, Toby A.
Shah, Nirav N.
Le Gouill, Steven
Dreyling, Martin
Vandenberghe, Elisabeth
Jurczak, Wojciech
Wang, Yucai
Cheah, Chan Y.
Gandhi, Mitul
Chay, Christopher
Sharman, Jeff
Andorsky, David J.
Song, Yuqin
Stark, Amy
Muthig, Valerie
Wang, Michael L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S395 - S396
[26] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenstrom Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
Palomba, M. Lia
Patel, Manish R.
Eyre, Toby A.
Jurczak, Wojciech
Lewis, David John
Gastinne, Thomas
Ma, Shuo
Cohen, Jonathon B.
Patel, Krish
Brown, Jennifer R.
Scarfo, Lydia
Munir, Talha
Lech-Maranda, Ewa
Hoffmann, Marc
Ujjani, Chaitra S.
Fakhri, Bita
Wang, Michael L.
Izutsu, Koji
Nagai, Hirokazu
Tam, Constantine S.
Seymour, John F.
Rhodes, Joanna M.
Vose, Julie M.
McKinney, Matthew
Gerson, James N.
Barve, Minal A.
Kuss, Bryone J.
Koh, Youngil
Gao, Wei
Ruppert, Amy S.
Walgren, Richard A.
Tsai, Donald E.
Nair, Binoj
Bao, Katherine
Mato, Anthony R.
Cheah, Chan Y.
BLOOD, 2022, 140
[27] Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
Shah, Nirav N.
Wang, Michael L.
Brown, Jennifer R.
Patel, Krish
Woyach, Jennifer A.
Wierda, William G.
Ujjani, Chaitra S.
Eyre, Toby A.
Zinzani, Pier Luigi
Alencar, Alvaro J.
Gastinne, Thomas
Ghia, Paolo
Lamanna, Nicole
Hoffmann, Marc
Patel, Manish R.
Flinn, Ian W.
Gerson, James N.
Ma, Shuo
Coombs, Catherine C.
Cheah, Chan Y.
Lech-Maranda, Ewa
Fakhri, Bita
Kim, Won-Seog
Barve, Minal A.
Cohen, Jonathon B.
Jurczak, Wojciech
Munir, Talha
Thompson, Meghan C.
Roeker, Lindsey E.
Bao, Katherine
Cangemi, Nicholas A.
Kherani, Jennifer F.
Walgren, Richard A.
Han, Hongmei
Ruppert, Amy S.
Mato, Anthony R.
BLOOD, 2022, 140 : 4127 - 4132
[28] BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naive mantle cell lymphoma.
Wang, Michael
Eyre, Toby A.
Shah, Nirav Niranjan
Le Gouill, Steven
Dreyling, Martin H.
Vandenberghe, Elisabeth
Wang, Yucai
Cheah, Chan
Song, Yuqin
Gandhi, Mitul
Chay, Christopher H.
Sharman, Jeff Porter
Andorsky, David Jacob
Ruppert, Amy S.
Duann, Chi-Wei
Muthig, Valerie A.
Ito, Rodrigo
Jurczak, Wojciech
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Coombs, Catherine C.
Pagel, John M.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Y.
Roeker, Lindsey
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David J.
Gerson, James N.
Alencar, Alvaro
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S315 - S316
[30] BRUIN MCL-321: A Phase 3 Open-Label, Randomised Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress)
Eyre, Toby
Shah, Nirav
Le Gouill, Steven
Dreyling, Martin
Vandenberghe, Elisabeth
Jurczak, Wojciech
Wang, Yucai
Cheah, Chan
Gandhi, Mitul
Chay, Christopher
Sharman, Jeff
Andorsky, David
Yin, Ming
Balbas, Minna
Kherani, Jennifer
Wang, Michael
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 117 - 118

← 1 2 3 4 5 →